Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 15, 2018-- Five Prime Therapeutics, Inc . (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Bryan Irving , Ph.D., as Executive Vice President and
Toggle Summary Five Prime Therapeutics Announces First Quarter 2018 Financial Results
Cabiralizumab advanced into a randomized Phase 2 trial in pancreatic cancer Five Prime initiated the Phase 1 portion of the FIGHT Phase 1/3 global registrational trial of bemarituzumab in gastric cancer FPA150, a first-in-class B7-H4 antibody, entered a Phase 1 monotherapy trial SOUTH SAN

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Tuesday, January 09, 2018 4:30 PM PST
Summary Toggle Tuesday, January 09, 2018 4:30 PM PST

36th Annual J.P. Morgan Healthcare Conference


Aron Knickerbocker
Senior Vice President and Chief Business Officer
Summary Toggle Wednesday, February 14, 2018 11:30 AM EST